Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing
Market News Market Pulse Stocks News ETF News Crypto News

Compass Therapeutics

Contributing Author

Recent Articles by Compass Therapeutics

Aug-06
Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update CMPX +5.29% GlobeNewswire
Jul-17
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026 CMPX GlobeNewswire
May-28
Compass Therapeutics to Participate in Upcoming June Investor Events CMPX +6.17% GlobeNewswire
May-21
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting CMPX CMPX +7.25% GlobeNewswire
May-12
Compass Therapeutics to Participate in Upcoming May Investor Events CMPX GlobeNewswire
May-05
Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update CMPX GlobeNewswire
Apr-27
Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer CMPX -64.41% GlobeNewswire
Apr-24
Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer CMPX GlobeNewswire
Mar-05
Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update CMPX GlobeNewswire
Jan-06
Compass Therapeutics Provides Corporate Update CMPX GlobeNewswire
Jan-05
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CMPX GlobeNewswire
Jan-05
Compass Therapeutics Announces Key Leadership Appointments CMPX GlobeNewswire
Dec-17
Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference CMPX -5.34% GlobeNewswire
Nov-25
Compass Therapeutics to Participate in Upcoming December Investor Events CMPX GlobeNewswire
Nov-05
Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update CMPX GlobeNewswire
Nov-04
Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting CMPX GlobeNewswire
Nov-03
Compass Therapeutics to Participate in Upcoming November Investor Events CMPX GlobeNewswire
Aug-26
Compass Therapeutics to Participate in Upcoming September Investor Events CMPX GlobeNewswire
Aug-12
Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering CMPX GlobeNewswire
Aug-12
Compass Therapeutics Announces Proposed Public Offering CMPX -5.09% GlobeNewswire
Aug-11
Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update CMPX +23.70% GlobeNewswire
Aug-08
Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025 CMPX GlobeNewswire
May-28
Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference CMPX GlobeNewswire
May-08
Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update CMPX GlobeNewswire
May-06
Compass Therapeutics to Participate in Upcoming May Investor Events CMPX -9.14% GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 1 minute for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)